Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist J.C. Walter Jr. Transplant Center - Houston, TX

Current/On-going Research

Dr. Joseph Galati

Total: 14 projects

  1. Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects with Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation – active.

  2. Satavaptan in the Prevention of Ascites Recurrence: a double-blind, randomized, parallel-group comparison of satavaptan at 5 to 10 mg daily versus placebo in the absence of diuretics in patients with recurrent ascites due to cirrhosis of the liver – 2008.

  3. Satavaptan in the Prevention of Ascites Recurrence: a double-blind, randomized, parallel-group comparison of satavaptan at 5 to 10 mg daily versus placebo with concomitant diuretics in patients with recurrent ascites due to cirrhosis of the liver – active.

  4. P03523-A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects with Chronic Hepatitis C Infected with Genotype 1 – active.

  5. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 MG BID for 6 Months in Preventing Hepatic Encephalopathy – active.

  6. A Multi-Center, Open Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects with A History of Hepatic Encephalopathy - active.

  7. Protocol HGS1008-C1060: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNα2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1 (ACHIEVE-1)- active

  8. Long-Term Follow-up of Subjects in a Phase 2 or 3 Clinical Trial in Which SCH 503034 was Adminsitered for the Treatment of Chronic Hepatitis C –active

  9. An Open-Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies.

  10. A Phase 3b, Randomized, Double-Blind, Double Dummy Study Evaluating the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy versus Emtriciabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects with Chronic Hepatitis B who are resistant to Lamivudine.

  11. A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD).

  12. A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin.

  13. A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1.

  14. A Randomized, Double-Blind, Placebo-controlled, Phase III trial of 2 regimens of Telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) in subjects with Chronic genotype 1 Hepatitis C infection who failed prior pegylated interferon plus Ribavirin treatment.